Why Roche Oncology Bet Big On Neoantigen-Directed T-Cell Therapy

 
• By Emily Hayes

In an interview at J.P. Morgan, Roche's James Sabry explained why it wants to lead the pack in personalized, neoantigen-directed cellular therapy, after announcing tie-up with Adaptive Biotechnologies.

Ship wheel, exploring new frontiers. Digital illustration. - Illustration
Roche wants to chart new directions in T-cell receptor therapies

More from Cell Therapies

More from Advanced Therapies